Tevogen Bio Holdings (TVGN) said Tuesday it's artificial intelligence initiative Tevogen.AI has launched a partnership with Microsoft (MSFT) to investigate potential treatments for human papilloma virus.
Tevogen said it has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T-cell targets to choose for a trial for TVGN 920, which will be its first oncology product.
"By leveraging Microsoft's cutting-edge AI and cloud technologies, we're able to accelerate our target identification and pre-clinical processes in ways that weren't previously possible," said Tevogen.AI Chief Information Officer and Head Mittul Mehta.
Financial details about the project weren't provided.
Price: 1.91, Change: -0.05, Percent Change: -2.81
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。